Tiziana's lower-dose foralumab cuts neuroinflammation in SPMS, but higher dose fails

Tiziana Life Sciences reported that its intranasal anti‑CD3 antibody, foralumab, lowered a neuroinflammation biomarker in patients with non‑active secondary progressive multiple sclerosis when given at a 50‑µg dose. The reduction in microglial activation was statistically significant after 12 weeks compared with placebo.

The same trial tested a 100‑µg dose, which did not meet the efficacy endpoint. While safety goals were achieved, the higher dose failed to show any benefit over placebo, leading the company to question the optimal dosing strategy.

Following the mixed results, Tiziana's shares fell about 17% at market open, trading near 67 cents. The outcome highlights the challenge of treating a form of MS that currently lacks FDA‑approved therapies, and the company may need to redesign the study or focus on the lower dose moving forward.